Answers are grounded in this paper and cite their sources.
PURPOSE: To map the development, contributors, collaboration patterns, influential publications, and thematic evolution of Behçet's uveitis research from 1981 to 2025. METHODS: Web of Science Core Collection (WoSCC) and Scopus were searched on June 5, 2026 (2,945 and 4,459 records). After filtering by publication year, document type, and language, 2,371 WoSCC and 3,043 Scopus records were screened for substantive ocular Behçet involvement. The final datasets included 1,239 WoSCC and 1,440 Scopus records (1,123 shared; 1,556 unique). The databases were analyzed separately using bibliometrix/Biblioshiny and VOSviewer. Publication growth was assessed by segmented Poisson regression. Thesaurus-harmonized author keywords were analyzed using thematic maps, thematic evolution, trend topics, and predefined theme groups with Cochran-Armitage trend testing. Türkiye led publication output in both databases. In both thematic maps, a biologic-treatment cluster centered on infliximab, biologics, and anti-tumor necrosis factor (anti-TNF) occupied the motor-theme region. Thematic evolution showed persistence of the Behçet disease core and parallel biologic-treatment and ocular/imaging-related themes. Biologic/targeted-therapy theme proportions peaked in 2010-2019 and were lower in 2020-2025; imaging-related keywords increased significantly in both databases, while retinal vascular inflammation/occlusive-disease keywords showed no significant temporal trend. CONCLUSION: Behçet's uveitis research expanded substantially; biologic therapy was a central theme, imaging-related keywords increased, and retinal vascular inflammation keywords showed no significant trend. These findings do not establish changes in clinical practice.
No takes yet. Share an insight, caveat, or question.
Çiftci et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: